The novel medication for the treatment of adults with major depressive disorder (MDD), Gepirone has eventually been approved by the FDA in late September following a long quest. Geprione belongs to the azapirone group, as the same class as buspirone. Gepirone acts as a full agonist at serotonin 5-HT1A autoreceptors and is generally, a partial agonist at postsynaptic serotonin 5-HT1A receptors. Gepirone has a unique antidepressant effect that relieves depressive symptoms without significant side effects.